Trials
2 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “AURN001 will be injected to the anterior chamber of the eye.”In the company’s words, NCT07368959 on ClinicalTrials.gov
- Tested for
- Corneal Edema (2 trials), Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
- Main trialPhase 3
- “The purpose of this study is to assess the efficacy and safety of single injection dose of AURN001 compared with placebo in adult participants with corneal edema secondary to corneal endothelial dysfunction.”In the company’s words, NCT07368959 on ClinicalTrials.gov
Other drugs for Corneal Edema
Coming up1
- Jun 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Jun 2027 | AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction | |
| Phase 2Active, not recruiting | Oct 2025 | Study of Cryopreserved AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction | |
| Phase 1/2Completed | 25 Oct 2024 | A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026